Beam plans to utilize an 'umbrella' clinical trial design, allowing multiple mutation-specific base editors to be developed ...
Beam Therapeutics posts a narrower Q4 loss as revenues surge past estimates. It secures $500M financing, extending its cash ...
After dumping its sole remaining gene therapy asset last year, Pfizer has decided to exercise its option for global rights to Beam Therapeutics’ liver-targeted gene editing candidate.
Beam Therapeutics has presented the first clinical data on its base editing technology. All four sickle cell disease patients in the efficacy cohort had fetal hemoglobin levels above Beam’s target—and ...
Beam Therapeutics BEAM shares are rising Tuesday after the company reported quarterly results. Beam Therapeutics stock is surging to new heights today. What’s fueling BEAM momentum? Beam Surpasses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results